Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Celiac Disease Pipeline Drugs Assessment Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Celiac Diseaseis a genetic autoimmune disease. It is caused due to the consumption of protein called gluten, which is found in barley, wheat,and rye. It enables damage the finger-like villi of small intestine and body will be unable to absorb nutrients into thebloodstream that leads to malnutrition. Symptoms of celiac disease include food allergy, watery and itchy eyes, difficulty in breathing, nausea, abdominal pain, mouth ulcers.

Celiac disease is diagnosed by serology tests and genetic tests. Treatment includes strict gluten-free diet. There are no FDA approved drugs to treat celiac disease.

Key developments: 

  • In November 2017, ImmusanT, Inc.raised $40 million Series C equity financing from ARCH Venture Partners and Vatera Healthcare Partners to proceedPhase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen DQ2.5 (HLA-DQ2.5) immune recognition gene.
  • In February 2016, Innovate Biopharmaceuticals Inc., completed an agreement to license Alba Therapeutics assets relating to larazotide acetate, a tight junction regulator, progressing toward Phase 3 clinical trials for the treatment of celiac disease.
  • In December 2015, Takeda Pharmaceutical Company Limited and Cour Pharmaceutical Development Company, Inc. entered into a partnership to research and develop novel immune modulating therapies for the potential treatment of celiac disease
  • In March 2015, Falk Pharma and Zedira entered into a collaboration to perform Phase 1 clinical trials of ED1227, a direct-acting inhibitor of tissue transglutaminase. The small molecule targets the dysregulated transglutaminase within the small intestine in order to dampen the immune response to gluten which drives the celiac disease process.

 

 

Celiac Disease Pipeline Drugs Assessment Dynamics

Celiac Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Celiac Disease treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Celiac Disease pipeline drugs development. This report studies the dynamics of the Celiac Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Celiac Disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

 

Celiac Disease Pipeline Drugs Assessment Segmentation Analysis

Report Benchmarks

Details

By Drugs

  • Larazotide
  • Pancrelipase
  • Rifaximin
  • Triamcinolone
  • Bupivacaine

By Route of Administration

  • Oral
  • Parenteral

By Trial Phase

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

 

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

 

  1. Executive Summary
  2. Global Celiac Disease Pipeline Drugs Assessment Market Introduction
    • Global Celiac Disease Pipeline Drugs Assessment Market Taxonomy
    • Global Celiac Disease Pipeline Drugs Assessment Market Definitions
      • Drugs
      • Route of Administration
      • Trial Phase
  1. Global Celiac Disease Pipeline Drugs Assessment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Celiac Disease Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis
    • Global Celiac Disease Pipeline Drugs Assessment Market Competition Landscape
    • Epidemiology
  2. Global Celiac Disease Pipeline Drugs Assessment Market Analysis,2019 - 2023 and Forecast, 2019 -  2030
    • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Celiac Disease Pipeline Drugs Assessment Market, By Drugs, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Larazotide
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Pancrelipase
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Rifaximin
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Triamcinolone
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Bupivacaine
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Celiac Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration, 2019 - 2023 and Forecast, 2018 2024
    • Oral
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Celiac Disease Pipeline Drugs Assessment Market Forecast, By Trial Phase, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Preclinical
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 1
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 2
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 3
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 4
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Celiac Disease Pipeline Drugs Assessment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Region, 2018 2024
  2. North America Celiac Disease Pipeline Drugs Assessment MarketAnalysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Larazotide
      • Pancrelipase
      • Rifaximin
      • Triamcinolone
      • Bupivacaine
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Country Analysis 2016 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Country, 2018 2024
    • North America Celiac Disease Pipeline Drugs Assessment Market Dynamics Trends
  3. Europe Celiac Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Larazotide
      • Pancrelipase
      • Rifaximin
      • Triamcinolone
      • Bupivacaine
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Country, 2018 2024
    • Europe Celiac Disease Pipeline Drugs Assessment Market Dynamics Trends
  4. Asia-Pacific Celiac Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Larazotide
      • Pancrelipase
      • Rifaximin
      • Triamcinolone
      • Bupivacaine
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Country Analysis2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Country, 2018 2024
    • Asia-Pacific Celiac Disease Pipeline Drugs Assessment Market Dynamics Trends
  5. Latin America Celiac Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Larazotide
      • Pancrelipase
      • Rifaximin
      • Triamcinolone
      • Bupivacaine
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Country, 2018 2024
    • Latin America Celiac Disease Pipeline Drugs Assessment Market Dynamics Trends
  6. Middle East and Africa Celiac Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Larazotide
      • Pancrelipase
      • Rifaximin
      • Triamcinolone
      • Bupivacaine
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Preclinical
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Celiac Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Drugs, By Route of Administration, By Trial Phase, and Country, 2018 2024
    • MEA Celiac Disease Pipeline Drugs Assessment Market Dynamics Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drugs& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • AMYRA Biotech AG (Switzerland)
      • Avaxia Biologics, Inc. (U.S.)
      • Calypso Biotech SA (Switzerland)
      • Provid Pharmaceuticals Inc. (U.S.)
      • Sitari Pharmaceuticals (U.S.)
      • Cour Pharmaceuticals (U.S.)
      • Glenmark Pharmaceuticals Ltd. (India)
      • Innovate Biopharmaceuticals (U.S.)
      • Others
  1. Research Methodology
  2. Key Assumptions and Acronyms

 

Key Market Players

  • AMYRA Biotech AG (Switzerland)
  • Avaxia Biologics, Inc. (U.S.)
  • Calypso Biotech SA (Switzerland)
  • Provid Pharmaceuticals Inc. (U.S.)
  • Sitari Pharmaceuticals (U.S.)
  • Cour Pharmaceuticals (U.S.)
  • Glenmark Pharmaceuticals Ltd. (India)
  • Innovate Biopharmaceuticals (U.S.)

Related Industry Reports